Brian Druker, director of the Knight Cancer Institute at OHSU, is critical of pharmaceutical companies’ profit margins. He co-authored a newly published letter in a the medical journal Blood criticizing the expense of a drug he helped develop. That drug, Gleevec, is now used by over 200,000 cancer patients worldwide, and can cost up to $100,000 a year. Dr. Druker hopes to begin working with lawmakers to change the way pharmaceutical companies price their drugs.
Have you or a loved one been through cancer treatment? What were the financial barriers to your treatment? Would you support governmental regulating pharmaceutical pricing?